Quince Therapeutics is a clinical stage biopharmaceutical company focused on therapeutic approaches to improve the lives of patients diagnosed with Alzheimer's and degenerative diseases. Co.'s portfolio of gingipain inhibitors are orally administered, brain-penetrating small molecules. Co.'s pipeline includes proprietary drug candidates for the treatment of CNS disorders including Alzheimer's disease, for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of conditions like periodontitis. Co.'s pipeline also includes proprietary irreversible protease inhibitors under development for the treatment of coronavirus infection. The QNCX average annual return since 2019 is shown above.
The Average Annual Return on the QNCX average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether QNCX average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the QNCX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free QNCX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
